-+ 0.00%
-+ 0.00%
-+ 0.00%

Silexion Therapeutics says warrant exercises raise USD 1 million gross proceeds

PUBT·05/15/2026 12:27:40
Listen to the news
Silexion Therapeutics says warrant exercises raise USD 1 million gross proceeds
  • Silexion Therapeutics entered definitive agreements for immediate cash exercise of outstanding warrants covering 1,995,092 ordinary shares at reduced exercise price of USD 0.5 per share.
  • Gross proceeds expected at about USD 1 million; closing expected on or about May 18, 2026.
  • In exchange, investors to receive unregistered Series C warrants for 2,045,000 shares and unregistered Series D warrants for 1,945,184 shares, each exercisable at USD 0.5 per share subject to shareholder approval.
  • Series C warrants set to expire five years from later of shareholder approval or effectiveness of resale registration statement; Series D warrants set to expire 24 months from same later date.
  • Company agreed to file resale registration statement for shares underlying new warrants.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605150827PRIMZONEFULLFEED1001182200) on May 15, 2026, and is solely responsible for the information contained therein.